These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

398 related articles for article (PubMed ID: 22074425)

  • 61. Antibody-directed enzyme prodrug therapy.
    Connors TA
    Cancer Cells; 1990 Feb; 2(2):56-7. PubMed ID: 2397145
    [No Abstract]   [Full Text] [Related]  

  • 62. Noninvasive optical imaging of nitroreductase gene-directed enzyme prodrug therapy system in living animals.
    Bhaumik S; Sekar TV; Depuy J; Klimash J; Paulmurugan R
    Gene Ther; 2012 Mar; 19(3):295-302. PubMed ID: 21753794
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Selective treatment of cancer: synthesis, biological evaluation and structural elucidation of novel analogues of the antibiotic CC-1065 and the duocarmycins.
    Tietze LF; Major F; Schuberth I; Spiegl DA; Krewer B; Maksimenka K; Bringmann G; Magull J
    Chemistry; 2007; 13(16):4396-409. PubMed ID: 17455190
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Antibody-directed enzyme prodrug therapy (ADEPT) with mustard prodrugs.
    Springer CJ; Niculescu-Duvaz I
    Anticancer Drug Des; 1995 Jul; 10(5):361-72. PubMed ID: 7639927
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Proteases as activators for cytotoxic prodrugs in antitumor therapy.
    Weidle UH; Tiefenthaler G; Georges G
    Cancer Genomics Proteomics; 2014; 11(2):67-79. PubMed ID: 24709544
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Determination of the biological activity and structure activity relationships of drugs based on the highly cytotoxic duocarmycins and CC-1065.
    Tietze LF; Krewer B; von Hof JM; Frauendorf H; Schuberth I
    Toxins (Basel); 2009 Dec; 1(2):134-50. PubMed ID: 22069536
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Carboxypeptidase-G2-based gene-directed enzyme-prodrug therapy: a new weapon in the GDEPT armoury.
    Hedley D; Ogilvie L; Springer C
    Nat Rev Cancer; 2007 Nov; 7(11):870-9. PubMed ID: 17943135
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Antibody directed enzyme prodrug therapy (ADEPT). A review of some theoretical, experimental and clinical aspects.
    Bagshawe KD; Sharma SK; Springer CJ; Rogers GT
    Ann Oncol; 1994 Dec; 5(10):879-91. PubMed ID: 7696159
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Design, Synthesis and Studies on Novel Polymeric Prodrugs of Erlotinib for Colon Drug Delivery.
    Kumar S; Sharma B; Bhardwaj TR; Singh RK
    Anticancer Agents Med Chem; 2021; 21(3):383-392. PubMed ID: 32781967
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Microbial Enzymes used in Prodrug Activation for Cancer Therapy: Insights and Future Perspectives.
    Dhankhar R; Kawatra A; Mohanty A; Gulati P
    Curr Protein Pept Sci; 2021; 22(7):514-525. PubMed ID: 33290198
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Folate-targeted enzyme prodrug cancer therapy utilizing penicillin-V amidase and a doxorubicin prodrug.
    Lu JY; Lowe DA; Kennedy MD; Low PS
    J Drug Target; 1999; 7(1):43-53. PubMed ID: 10614814
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Enhanced cytotoxicity with a novel system combining the paclitaxel-2'-ethylcarbonate prodrug and an HSV amplicon with an attenuated replication-competent virus, HF10 as a helper virus.
    Ishida D; Nawa A; Tanino T; Goshima F; Luo CH; Iwaki M; Kajiyama H; Shibata K; Yamamoto E; Ino K; Tsurumi T; Nishiyama Y; Kikkawa F
    Cancer Lett; 2010 Feb; 288(1):17-27. PubMed ID: 19604626
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Antibody-directed enzyme/prodrug therapy (ADEPT).
    Bagshawe KD
    Biochem Soc Trans; 1990 Oct; 18(5):750-2. PubMed ID: 2083666
    [No Abstract]   [Full Text] [Related]  

  • 74. Targeting Toxins toward Tumors.
    Franzyk H; Christensen SB
    Molecules; 2021 Feb; 26(5):. PubMed ID: 33673582
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Selective cancer therapy by extracellular activation of a highly potent glycosidic duocarmycin analogue.
    Chen KC; Schmuck K; Tietze LF; Roffler SR
    Mol Pharm; 2013 May; 10(5):1773-82. PubMed ID: 23448264
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Introduction to the background, principles, and state of the art in suicide gene therapy.
    Niculescu-Duvaz I; Springer CJ
    Mol Biotechnol; 2005 May; 30(1):71-88. PubMed ID: 15805578
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Preclinical evaluation of a prostate-targeted gene-directed enzyme prodrug therapy delivered by ovine atadenovirus.
    Wang XY; Martiniello-Wilks R; Shaw JM; Ho T; Coulston N; Cooke-Yarborough C; Molloy PL; Cameron F; Moghaddam M; Lockett TJ; Webster LK; Smith IK; Both GW; Russell PJ
    Gene Ther; 2004 Nov; 11(21):1559-67. PubMed ID: 15343359
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Developments with targeted enzymes in cancer therapy.
    Bagshawe KD; Sharma SK; Burke PJ; Melton RG; Knox RJ
    Curr Opin Immunol; 1999 Oct; 11(5):579-83. PubMed ID: 10508703
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Discovery and evaluation of Escherichia coli nitroreductases that activate the anti-cancer prodrug CB1954.
    Prosser GA; Copp JN; Syddall SP; Williams EM; Smaill JB; Wilson WR; Patterson AV; Ackerley DF
    Biochem Pharmacol; 2010 Mar; 79(5):678-87. PubMed ID: 19852945
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Novel fluorinated prodrugs for activation by carboxypeptidase G2 showing good in vivo antitumor activity in gene-directed enzyme prodrug therapy.
    Davies LC; Friedlos F; Hedley D; Martin J; Ogilvie LM; Scanlon IJ; Springer CJ
    J Med Chem; 2005 Aug; 48(16):5321-8. PubMed ID: 16078849
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 20.